Show simple item record

dc.contributor.authorLeen, Brendan
dc.contributor.authorWhite, Gethin
dc.contributor.authorCarrigan, Marie
dc.contributor.authorO'Reilly, Peter
dc.contributor.authorBambury, Niamh
dc.contributor.authorCasey, Geraldine
dc.contributor.authorBeatty, Kenneth
dc.contributor.authorMullane, Paul
dc.contributor.authorWhite, Philippa
dc.date.accessioned2021-08-20T15:37:45Z
dc.date.available2021-08-20T15:37:45Z
dc.date.issued2021-08
dc.identifier.urihttp://hdl.handle.net/10147/630148
dc.descriptionMain Points 1. The WHO and CDC recommend that in exceptional epidemiological circumstances, countries may consider extending the dosing interval to a maximum of 42 days . Currently, only limited data are available on the efficacy of mRNA COVID 19 vaccines administered beyond the 42 day window. 2. Modelling studies suggest that initially vaccinating a greater number of people with a single dose will prevent more deaths and hospitalizations than vaccinating a smaller number of people w ith 2 doses ; and that extending the dosing interval shows progressive benefit to population immunity 3. Data suggest that the second dose should not be delayed in t hose >65 years of age or in immunosuppressed individuals such as cancer patients or transplant recipients due to reduced vaccine immunogenicity after the first dose.en_US
dc.language.isoenen_US
dc.publisherHealth Service Executiveen_US
dc.relation.ispartofseriesQ.207en_US
dc.subjectCoronavirusen_US
dc.subjectCOVID-19en_US
dc.subjectVACCINATIONen_US
dc.subjectIMMUNISATIONen_US
dc.title[Evidence summary]: Is there evidence of mRNA vaccine effectiveness with an extended dosing interval? If so, what is the interval? [V1.0]en_US
dc.typeOtheren_US
refterms.dateFOA2021-08-20T15:37:46Z


Files in this item

Thumbnail
Name:
Q207 [Evidence Summary] COVID-19 ...
Size:
1.997Mb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record